Srdan Verstovsek, MD, PhD / Ruben A. Mesa, MD, FACP - Understanding the Clinical Spectrum of Myelofibrosis: Expert Perspectives on Molecular Biology, JAK Inhibitors, and Emerging Therapeutics

1:20:00
 
שתפו
 

Fetch error

Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on January 20, 2022 21:08 (8d ago)

What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.

Manage episode 304994615 series 103592
על ידי PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education התגלה על ידי Player FM והקהילה שלנו - זכויות היוצרים שמורות למפרסם, לא ל-Player FM, והשמע מוזרם ישירות מהשרתים שלכם. הירשמו כדי לעקוב אחר עדכונים ב-Player FM, או הדביקו את כתובת העדכונים באפליקציות פודקאסט אחרות.
Go online to PeerView.com/ZZW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in myelofibrosis discuss risk stratification, individualized care, and treatment strategies, including the use of JAK inhibitors and JAK inhibitor–based combinations. Upon completion of this accredited CE activity, participants should be better able to: Review modern risk stratification models, molecular features, cytogenetics, and clinical presentation of myelofibrosis, Evaluate the latest safety, efficacy, and tolerability data supporting the use of JAK inhibitors and other novel strategies, including JAK inhibitor–based combinations or sequencing approaches for managing transplant-eligible and transplant-ineligible patients with myelofibrosis, Address practical aspects of individualized care and risk-adapted therapy in myelofibrosis for managing lower- and higher-risk patients, including those failing prior JAK inhibitor therapy, Educate patients on the treatment strategies, what to expect when undergoing treatment with JAK inhibitor or JAK inhibitor–based combinations, and how they can effectively collaborate with the oncology team to monitor and manage therapy-related adverse events.

366 פרקים